Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAP-CAP adaptive platform trial for community-acquired pneumonia
NL-OMON53023Phase 4Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of ceftriaxone, amoxicillin + clavulanate, ceftaroline fosamil, piperacillin + tazobactam, moxifloxacin and 15 more, sponsored by University Medical Center Utrecht. Started Apr 2016; status: recruiting.
02
Drugs
ceftriaxoneamoxicillin + clavulanateceftaroline fosamilpiperacillin + tazobactammoxifloxacin
Beyond the preview
Go deeper on NL-OMON53023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53023.